Cargando…
External validation of a genitourinary cancer-specific prognostic scoring system to predict survival for patients with bone metastasis (modified B-FOM scoring model): Comparison with other scoring models in terms of accuracy
OBJECTIVE: We previously developed genitourinary (GU) cancer-specific scoring system for prediction of survival in patients with bone metastasis (the Bone-Fujimoto-Owari-Miyake [B-FOM] scoring model) based on five prognostic factors: the type of primary tumor (prostate cancer (PCa) vs renal cell car...
Autores principales: | Owari, Takuya, Miyake, Makito, Nakai, Yasushi, Tanaka, Nobumichi, Itami, Yoshitaka, Hirao, Shuya, Momose, Hitoshi, Nakagawa, Yoshinori, Iida, Kouta, Maesaka, Fumisato, Shimizu, Takuto, Iemura, Yusuke, Matsumoto, Yoshihiro, Kuwada, Masaomi, Otani, Takeshi, Otsuka, Kenji, Okajima, Eijiro, Hosokawa, Yukinari, Okamura, Ryosuke, Fujimoto, Kiyohide |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7770480/ https://www.ncbi.nlm.nih.gov/pubmed/33384916 http://dx.doi.org/10.1016/j.jbo.2020.100344 |
Ejemplares similares
-
Optimal timing of ureteroscopic lithotripsy after the initial drainage treatment and risk factors for postoperative febrile urinary tract infection in patients with obstructive pyelonephritis: a retrospective study
por: Itami, Yoshitaka, et al.
Publicado: (2021) -
Amrubicin is effective against small cell carcinoma of the prostate as a second‐line chemotherapeutic agent: A case report
por: Maesaka, Fumisato, et al.
Publicado: (2019) -
Unexpected presentation of allograft dysfunction triggered by page kidney phenomenon immediately after kidney transplantation: a case report
por: Hori, Shunta, et al.
Publicado: (2018) -
Hypomethylation of CLDN4 Gene Promoter Is Associated with Malignant Phenotype in Urinary Bladder Cancer
por: Maesaka, Fumisato, et al.
Publicado: (2022) -
Clinical Impact of Sarcopenia and Inflammatory/Nutritional Markers in Patients with Unresectable Metastatic Urothelial Carcinoma Treated with Pembrolizumab
por: Shimizu, Takuto, et al.
Publicado: (2020)